Metabolic Stability and Targeted Delivery of Oligonucleotides: Advancing RNA Therapeutics Beyond The Liver
Journal of Medicinal Chemistry · 10.04.2025 · 68 (7) · 6870-6896
DOI: 10.1021/acs.jmedchem.4c02528 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 08.01.2025. Verfasst von Puneet Anand und 3 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Genetic Medicines, Regeneron Pharmaceuticals, Inc., Tarrytown, New York 10591, United States. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Oligonucleotides, Drug Delivery Systems, RNA, Small Interfering. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 238 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Oligonucleotides have emerged as a formidable new class of nucleic acid therapeutics. Fully modified oligonucleotides exhibit enhanced metabolic stability and display successful clinical applicability for targets formerly considered "undruggable". Accumulating studies show that conjugation to targeting modalities of stabilized oligonucleotides, especially small interfering RNAs (siRNAs), has enabled robust delivery to intended cells/tissues. However, the major challenge in the field has been the stability and targeted delivery of oligonucleotides (siRNAs and antisense oligonucleotides (ASOs)) to extrahepatic tissues. In this Perspective, we review chemistry innovations and emerging delivery approaches that have revolutionized oligonucleotide drug discovery and development. We explore findings from both academia and industry that highlight the potential of oligonucleotides for indications involving different extrahepatic organs─including skeletal muscles, brain, lungs, skin, heart, adipose tissue, and eyes. In all, continued advances in chemistry coupled with conjugation-based approaches or novel administration routes will further advance the delivery of oligonucleotides to extrahepatic tissues.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Regeneron Genetic Medicines, Regeneron Pharmaceuticals, Inc., Tarrytown, New York 10591, United States.
ORCID-Profile: Puneet Anand
Zitieren
APA
Anand, P., Zhang, Y., Patil, S., & Kaur, K. (2025). Metabolic Stability and Targeted Delivery of Oligonucleotides: Advancing RNA Therapeutics Beyond The Liver. Journal of Medicinal Chemistry, 68(7), 6870-6896. https://doi.org/10.1021/acs.jmedchem.4c02528
Vancouver
Anand P, Zhang Y, Patil S, Kaur K. Metabolic Stability and Targeted Delivery of Oligonucleotides: Advancing RNA Therapeutics Beyond The Liver. Journal of Medicinal Chemistry. 2025;68(7):6870-6896. doi:10.1021/acs.jmedchem.4c02528
BibTeX
@article{Anand2025,
author = {Anand, Puneet and Zhang, Yu and Patil, Spoorthi and Kaur, Keerat},
title = {Metabolic Stability and Targeted Delivery of Oligonucleotides: Advancing RNA Therapeutics Beyond The Liver},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {7},
pages = {6870--6896},
doi = {10.1021/acs.jmedchem.4c02528}
}
EUVIMED